BBK Worldwide (BBK), a patient recruitment innovator for the clinical R&D segment of the pharmaceutical, biotechnology, and medical device industries, announces a strategic alliance with CROèe.
The Japanese pharmaceutical market is the second largest individual market in the world, with sales of $60 billion, which constitutes 11% of global pharmaceutical sales. Despite Japan’s market size, it typically takes 2.5 years longer for a drug to come to market in Japan than in most other countries.
“One immediate result of the partnership will be the ability to offer research sponsors a more reliable process for site identification and selection. BBK’s physician database, the BIO NotifierSM, combined with CROèe’s patient database, will serve as a resource to help clinical trial sponsors quickly and efficiently find appropriate patients and investigators of which they had previously been unaware,” comments Sho Ando, President, CROèe. “I am looking forward to being able to introduce global standards of patient recruitment and analysis to the Japanese market, and to contribute to an increased public understanding of clinical research,” continues Ando.
The formation of the alliance further demonstrates BBK’s commitment to industry growth within the region, having established an office in Osaka, Japan in 2009. CROèe will join a network of companies that make up the BBK Worldwide Alliance – companies that have been vetted for their demonstrated ability to provide sophisticated patient recruitment services in their country or region. Under BBK’s direction, the members of the BBK Worldwide Alliance provide clients with the most extensive recruitment capabilities available in the world today.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.